Aisling Capital Management LP Nuvation Bio Inc. Transaction History
Aisling Capital Management LP
- $273 Million
- Q4 2024
A detailed history of Aisling Capital Management LP transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Aisling Capital Management LP holds 2,541,009 shares of NUVB stock, worth $5.62 Million. This represents 2.48% of its overall portfolio holdings.
Number of Shares
2,541,009
Previous 2,541,009
-0.0%
Holding current value
$5.62 Million
Previous $5.84 Million
15.66%
% of portfolio
2.48%
Previous 2.4%
Shares
1 transactions
Others Institutions Holding NUVB
# of Institutions
163Shares Held
151MCall Options Held
1.2KPut Options Held
223K-
Decheng Capital LLC Menlo Park, CA26MShares$57.4 Million14.81% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$35.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.7MShares$34.8 Million0.0% of portfolio
-
Omega Fund Management, LLC Boston, MA13.1MShares$28.9 Million53.05% of portfolio
-
Octagon Capital Advisors LP New York, NY9.2MShares$20.3 Million5.46% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $480M
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...